INTRODUCTION
The incidence of Inflammatory Bowel Disease (IBD) has seen a rapid increase over the past decades, specifically in the populations of Western Europe and North America (Cosnes, Gower-Rousseau, Seksik, & Cortot, 2011; Ghione et al., 2017; Loftus, 2004) . One of the most common forms of IBD is Ulcerative Colitis (UC), a chronic condition that is characterized by mucosal inflammation and ulcers on the inner lining of the human colon and rectum (Conrad, Roggenbuck, & Laass, 2014) . It is estimated that worldwide 150 out of every 100,000 people suffer from UC, although prevalence numbers appear to be positively correlated with the adoption of 'Western' dietary habits (Cosnes et al., 2011 ; da Silva, Lyra, Rocha, & Santana, 2014; Feuerstein & Cheifetz, 2014; Loftus, 2004; Sartor, 2006) . In the United Kingdom, for example, ten-fold higher incidence rates have been observed compared to Singapore, Korea or Japan (Cosnes et al., 2011; da Silva et al., 2014; Feuerstein & Cheifetz, 2014; Loftus, 2004; Sartor, 2006) . Typical symptoms of UC include abdominal pain, tenesmus, (bloody) diarrhea, rectal bleeding, lack of appetite, fever and fatigue (Conrad et al., 2014) . Furthermore, UC may manifest itself outside of the gastrointestinal tract, for instance in the form of episcleritis, uveitis, arthropathy or sclerosing cholangitis (Jess, Gamborg, Munkholm, & Sørensen, 2007 ; Kemp, Griffiths, & Lovell, 2012) . However, due to the disease's relapsing and remitting clinical course, presented symptoms and their severity may vary significantly-both between and within patients (da Silva et al., 2014) . Approximately half of patients are asymptomatic at a given point in time, whereas the other 50% suffers from mild to severe clinical symptoms (Sachar, 1998) . In addition, an estimated 20-30% of patients develop an acute severe flare at some point during the course of their disease that requires urgent hospitalization and may present life-threatening complications (Dulai & Jairath, 2018) .
Clinical management of UC is focused primarily on inducing and maintaining clinical remission (Feuerstein & Cheifetz, 2014; Kruis et al., 2004) . To this end, the first line of treatment consists of aminosalicylates such as sulfasalazine or mesalazine, and in moderate to severe patients, corticosteroids are concurrently administered (Dulai & Jairath, 2018; Feuerstein & Cheifetz, 2014; Yoshimatsu et al., 2015) . However, aminosalicylates are not sufficiently effective in maintaining remission rates (Feuerstein & Cheifetz, 2014; Kruis et al., 2004) , and repeated and long-term use of high-dose steroids is associated with significant adverse events, such as adrenal insufficiency, osteoporosis, aseptic joint necrosis, depression or psychosis (Buchman, 2001; Warrington & Bostwick, 2006) . Furthermore, 30-40% of patients will likely not respond to steroids and require additional treatment with second-line therapies such as infliximab or cyclosporine (Dulai & Jairath, 2018) . These second-line therapies are associated with a significant risk of adverse events as well, including paresthesias, infection, nephrotoxicity, and abnormal liver functioning (Kohn, Daperno, Armuzzi et al., 2007; Sternthal, Murphy, George et al., 2008) . Moreover, while inducing and maintaining a steroid-free clinical remission remains the standard of care (Feuerstein & Cheifetz, 2014) , UC is known to burden patients in ways that are not always clinically apparent and may therefore easily be ignored (Kemp et al., 2012; Pizzi et al., 2006) . In fact, it has been indicated that patients' subjective experience of health and quality of life (QoL) is only poorly correlated with the physiological measures of disease impact as conventionally applied in the clinic (Hjortswang, Ström, & Almer, 1998; Kemp et al., 2012) . A considerable body of evidence signals that conventional approaches in the clinical management of UC fail to capture the concerns, worries, inconveniences, and other less tangible impacts that are rooted in the disease (de Rooy et al., 2001; Kemp et al., 2012) .
Hence, it appears that the medical needs of UC patients are unmet, calling for novel approaches to alleviate the disease's impact on patients' QoL.
The intestinal microbiota may play a key role in the pathogenesis and disease mechanism of colitis (Campieri & Gionchetti, 2001) . Probiotic intervention has therefore been suggested as a safe and potentially effective addition to conventional treatment regimens for UC (Celiberto, Bedani, Rossi, & Cavallini, 2017 (Flach et al., 2017) , this lingering uncertainty regarding therapeutic effectiveness represents a significant barrier to probiotic innovation and utilization. Considering the promising potential of probiotics for UC patients, well-designed randomized controlled trials are warranted to address this innovation barrier. Such trials should involve outcome parameters that are appropriate both in terms of their relevance to the specific wants and needs of UC patients and to the probiotic formulation at hand.
In order to guide these future trials, the current study aims to establish which types of factors shape UC patients' subjective experience of QoL and, additionally, what parameters might be worthwhile to investigate in studies on probiotic intervention. To this end, we conducted an exploratory investigation in patients with UC, fully emphasizing the patient perspective by exploring the impacts of UC on QoL and the potential of a multispecies probiotic formulation to alleviate these impacts as perceived by patients themselves.
METHODS
To meet the research objective, the current study took an interpretative, constructionist approach. In-depth semi-structured interviews and inductive thematic coding were used to capture and thematically analyze the subjective experiences and perceptions of UC patients, in terms of the disease's impact on quality of life (QoL), specific probiotic effects, and the potential of probiotics in general. Not delimiting experiences and perceptions by pre-defined or measurable categories and thus allowing the inclusion of any relevant theme, the applied methodology particularly fits the highly integrated nature of the QoL concept-which makes it difficult to define and measure (Kappelman et al., 2014 )-as well as the relationship between QoL and probiotics in IBD-which remains elusive (Ghouri et al., 2014).
Interview participants
The study was conducted in patient volunteers between 18-70 who had been clinically diagnosed with UC (>1 year), had mild to moderate symptoms, did not suffer from comorbidity, and did not use probiotics. To optimize the likelihood of capturing all relevant themes, the number of interview participants was based on recommendations provided in the methodological literature on qualitative data saturation (Fugard & Potts, 2015; Guest, Bunce, & Johnson, 2016; Kerr, Nixon, & Wild, 2010) . A lower prevalence threshold of 20% was applied for themes to be considered relevant. Accepting a 90% probability of capturing the least prevalent theme (i.e., power), and assuming an 80% chance of patients actually expressing a theme upon its occurrence, a minimum number of 14 participants proved to be required. Patients were recruited via online communication channels of the Dutch patient association for IBD, 'Crohn & Colitis Ulcerosa Vereniging Nederland' (CCUVN), in October 2016.
Probiotic formulation
At recruitment by CCUVN, interview participants were given the opportunity to opt for a sample kit of the multispecies probiotic Ecologic® 825 (Winclove Probiotics B.V., The Netherlands, available on the Dutch market as Winbiotic® PRO•IB), containing nine bacterial strains (Bifidobacterium bifidum W23; Bifidobacterium lactis W51; Bifidobacterium lactis W52; Lactobacillus acidophilus W22; Lactobacillus casei W56; Lactobacillus paracasei W20; Lactobacillus plantarum W62; Lactobacillus salivarius W24; Lactobacillus lactis W19) with a total cell count of 2.5 x 10^9 colony forming units (cfu) per gram. Sample kits contained 84 sachets, each containing a daily dosage of 3 grams of the probiotic formulation (7.5 x 10^9 cfu per day in total) in powder form, to be ingested orally after dissolving in water, milk, or yoghurt.
Interview design
A single in-depth interview was conducted with each participant at least 6 weeks after the distribution of all sample kits by CCUVN, allowing for a sufficient period of daily consumption of the probiotic formulation-when opted for. All interviews were conducted by the same researcher, either face-to-face in the participant's home setting or via telephone, taking into account the participant's preference. A semi-structured interview guide (see Appendix for a translated example) was used to optimize (intra-rater) consistency. This guide was broadly structured according to the QoL impact domains as suggested by Devlen et al. (2014) for IBD in general. Hence it provided a sensitizing conceptual basis for the exploration of patient experiences and perceptions in the context of UC, while enabling the emergence of any altered or novel themes and domains present in the studied population (Charmaz & Belgrave, 2012).
Primary study parameters
Subjective experiences and perceptions of UC patients regarding the impact of UC on QoL, probiotic effects on QoL, and probiotics in general were the primary outcome parameters in the present study.
Data-processing and -analysis
All interviews were audiotaped and transcribed semi-verbatim (i.e., adhering to sentences and phrasing while editing grammatically incoherent content for purposes of clarity and readability) by the same researcher. Transcripts were coded and constructed into thematic categories in an iterative and comparative manner (Gray, 2013) . The resulting thematic framework was reviewed by two independent researchers and concurrently finalized.
RESULTS

Interview participants
A total of 23 UC patients were included in the present study, 14 of which reported to have opted for and used the multispecies probiotic formulation Ecologic® 825 during the period prior to the interview ('users') and 9 of which reported to have not ('non-users'). Characteristics of the interview participants are included in Table 6 .1. 
Impact of ulcerative colitis on patients' quality of life
Patients were asked about the broad impact of UC on their quality of life (QoL). Five distinct core impact domains were identified upon thematic analysis of the interview data, i.e., 'Physical', 'Psychological', 'Social Relationships', 'Lifestyle', and 'Daily Activities'. As visualized in the resulting conceptual model (Figure 6.1) , UC's broad impact on QoL was shown to be highly integrated, with effects in a certain domain affecting other domains in turn (e.g., the physical effect of being fatigued causing the social-relationship effect of being unable to attend to the needs of a spouse, in turn causing the psychological effect of being worried about the relationship with a spouse). Furthermore, while treatment may obviously have a beneficial impact on patient QoL by alleviating UC's direct effects in the five core domains, treatment-related effects take an inevitable share in the burden of living with the disease as well. Visualized by the mediating ring in Figure 6 .1, treatment-related and thereby indirect effects of UC were shown to affect all five QoL impact domains. The mean number of reported themes was significantly larger for female participants than for male participants (31.6 vs. 22.6; t(21) = -2.12, p < 0.05). Below, the most prevalent themes are discussed for each of the identified domains, as well as for treatment-related impact. An overview of all patient-reported impact themes and their absolute and relative reporting frequencies is provided in the appendix (Table A1 ).
Physical
Impact in the Physical domain relates to effects of UC perceived through the bodily senses as opposed to the mind. All 23 patients reported effects in the Physical domain, negatively impacting their QoL. The most commonly reported physical themes were being fatigued and therefore needing more rest (by 65% of total patient participants), bowel hypersensitivity to certain foods or drinks (61%), and an increased stool frequency or duration (43%).
Psychological
Impact in the Psychological domain relates to effects of UC perceived through the mind as opposed to the bodily senses. Again, all 23 patients reported to perceive psychological impact of UC, most often expressed as being worried or anxious about a variety of disease-related risks or imminent effects (by 91% of total patient participants), such as incontinence, developing cancer, disease progression, the need for a stoma, or having a fl are. Furthermore, 70% of patient participants reported feelings of loss of control-primarily caused by the often inexplicable links between symptoms and causes and the unpredictable course of the disease-to negatively impact their QoL. In addition, patients frequently communicated the notion of being unable to meet their former (healthy) standards of living and expectations for life (43%), aff ecting their psychological QoL. Other frequently mentioned themes in the Psychological domain were a diffi culty with identifying as chronically ill (26%) and the omnipresence of UC (26%).
Figure 6.1 Ulcerative colitis hampers patients' quality of life through fi ve interconnected domains.
QoL impact domains for UC as identifi ed from 23 in-depth patient interviews. UC's direct and indirect (treatment-related) impact in a certain domain is suggested to aff ect the other domains in turn, illustrating the interconnected and omnipresent nature of the disease's impact on patients' QoL.
Social Relationships
Impact in the Social Relationships domain relates to effects of UC on the properties of interactions with other individuals. Of the interviewed patients, 78% reported effects in this domain to negatively impact their social QoL. Patients often reported being burdened by a lack of understanding of their health condition, resulting from unfamiliarity with UC and the invisible nature of the disease (52%). Other high-prevalent impact themes within this domain were restricted participation in social events and the associated social separation (43%), the need to explain the disease to others (26%), and being unable to attend to the needs of a spouse, family or friends (22%).
Lifestyle
Impact in the Lifestyle domain relates to effects of UC on the patient's habits and behavior patterns. Of the interviewed patients, 70% mentioned lifestyle-related themes that hampered their QoL, all of which reporting some kind of behavioral or habitual change. The most prevalent of these were the restricted consumption of certain foods or drinks (52%) and the development of precautionary habits against sudden disease symptoms (17%). Furthermore, several patients (17%) reported a lack of spontaneity or excitement as a result of these modified behaviors to negatively affect their lifestyle-related QoL.
Daily Activities
Impact in the Daily Activities domain relates to effects of UC on the characteristics of the patient's 'daily doings', including work, school, parenting, household, and leisure-related activities. All 23 patients reported that UC negatively affected their QoL via impact in the Daily Activities domain, with 52% of patients indicating the need to quit a job or cut down on working and 48% mentioning hospitalization as a burdensome effect. Other frequently reported themes were the need to schedule the day according to the impact of UC (43% of patients)-often exemplified by the need to plan for several moments of rest to battle disease-related fatigue-and the disease being present in all activities in some way or another, thus dominating daily life (39%). Furthermore, patients often reported the notions of having to balance and prioritize their daily activities, having to quit or cut down on sports activities, and suffering from impaired professional or academic performance as a result of UC (each 30%). Identified daily-activity effects were grouped into three thematic categories, i.e., 'schedule and planning', 'travel and leisure', and 'occupational'.
Treatment-related impact
Treatment-related impact relates to effects that are rooted in the interventions that are taken in response to the patient's health condition. Treatment-related impact may therefore manifest itself in all of the five previously covered QoL impact domains, either indirectly by mediating UC's impact in these domains or through direct effects (e.g., physical side-effects of medication 
Probiotics for improving patients' quality of life
Patients were asked about any recent experiences with the consumption of probiotics. Of the 23 interview participants, 14 reported to have opted for and consumed the probiotic formulation Ecologic® 825 during the period prior to the interview ('users'). These participants were interviewed on the perceived impact of the formulation on their QoL.
Consumption characteristics
The 14 users had consumed the probiotic formulation for a mean total of 56 days at the moment of interviewing (Table 6 .2). Ten reported to have consumed the formulation on a daily basis accordant to the general instructions for use, while three reported near-daily consumption (i.e., 5-6 days per week). One user reported to have consumed the formulation on a mere occasional basis, being concerned about overstressing the intestine. Furthermore, one user reported to cease consumption of the probiotic formulation just prior to monitoring visits in the hospital, clarifying to be concerned that its potentially beneficial intestinal effects could persuade the | 156 | CHAPTER 6 practitioner to temper regular treatment, in turn increasing the chance of disease relapse. A summary of consumption characteristics is provided in Table 6 .2.
Effects
Nine users (64%) reported effects following consumption of the probiotic formulation, of which eight users reported positive effects (57%, 'responders') and one user reported a neutral effect (7%), i.e., an effect that was noticeable yet neither positively nor negatively correlated to QoL. The remaining five users (36%) indicated to have experienced no effect at all. No negative effects were associated with the consumption of the probiotic formulation. Female users significantly more often reported effects (t(12) = 2.34, p < 0.05) and significantly more often reported positive effects (t(12) = 3.48, p < 0.01) than male users. Patient-reported effects were sorted according to the previously identified QoL impact domains (see 6.4.2) and are discussed over the paragraphs below. The Physical domain appeared to be most positively affected by probiotic consumption, with 57% of users (100% of responders) reporting positive impact in this domain. Additionally, two users (14% of users; 25% of responders) reported positive impact of probiotic consumption in the Psychological domain. Effects are visualized in Figure 6 .2, and a complete list of patient-reported themes regarding probiotic effects is provided in Table 6 .3. 
Physical
Nine users (64%) reported to have perceived physical impact of consumption. Effects relating to bowel habits were most prevalent, with 57% of users reporting themes within this category. In this respect, users most often stated to have experienced a decrease in stool frequency and an enhanced stool texture (29% of users; 50% of responders). Furthermore, three users reported other bowel-related eff ects, such as a decrease in abdominal pain and rumbling and the feeling of having more intestinal 'resilience' (14% of users; 25% of responders), for instance refl ected in a quicker recovery from unpleasant intestinal sensations. Additional, less prevalent physical eff ect themes are included in Table 6 .3.
Psychological
Two users (14%) reported to have perceived psychological eff ects, with one user mentioning a good and healthy feeling as a consequence of consumption (7% of users; 13% of responders), and another indicating happiness as a result of experiencing positive physical eff ects (idem). Sixty-four percent of total users report physical eff ects and 14% report psychological eff ects.
.3.4.5 Social Relationships, Lifestyle, and Daily Activities
No specifi c eff ects were reported for the Social Relationships, Lifestyle, and Daily Activities impact domains as defi ned in 6.4.2.1 -6.4.2.1.5.
Effect relevance
Of the eight users reporting positive effects, four (29% of users; 50% of responders) indicated deeming these effects to be highly relevant in terms of improving their QoL, while three (21% of users; 38% of responders) reported the experienced effects to be moderately relevant in this respect. Of the latter three, one responder explained perceiving the effect of having stools with enhanced texture as a sign of increased intestinal health, rather than it directly improving QoL. Another explained the effect of a decreased stool frequency to be only moderately relevant, as stool frequency did only limitedly impact this user's QoL. The third reported experiencing a relatively low impact of the disease on QoL during the period of using the probiotic, leaving only room for moderately relevant effects. Non-relevance was reported by two of the users experiencing effects (14% of users; 13% of responders), one of which had only experienced an altered stool scent and the other clarifying that the effect of enhanced stool texture, while positive, disappeared too rapidly to bear relevance. In conclusion, 50% of users or 88% of responders reported a relevant impact of consuming the probiotic formulation.
Attitudes towards probiotic consumption
Patients, both users and non-users, were additionally interviewed on their attitudes towards probiotic consumption. All 23 interview participants expressed a positive general attitude towards probiotics, frequently reported by users as a curiosity towards the potential beneficial effects on their QoL (by 64% of users, 0% of non-users; 39% of total) and by both users and non-users as a belief in the underlying theoretical rationale (21% of users; 44% of non-users; 30% of total). Furthermore, 44% of non-users and 7% of users (22% of total) reported to be positive yet cautious, awaiting convincing evidence of beneficial effects. With respect to the consumption of probiotics specifically in the context of managing UC, frequently reported themes by both users and non-users were perceiving no harm in trying probiotics (50% of users; 33% of non-users; 43% of total) and not having any major expectations in terms of effects (21% of users; 33% of non-users; 26% of total). Additionally, while several participants expressed to have no specific effect expectations (29% of users; 11% of non-users; 22% of total), 22% of total participants perceived probiotics as particularly relevant for symptom alleviation during periods of gut disbalance or flares, expecting mild alleviation of disease symptoms in general and therefore to feel slightly better overall. Furthermore, participants often stated to expect a difficulty in linking the use of a probiotic to any perceived effects (29% of users; 33% of non-users; 30% of total. With regard to probiotic products, especially non-users reported to perceive good products as often too expensive (7% of users; 44% of non-users; 22% of total), as well as having little belief in the quality and efficacy of cheaper probiotic alternatives (7% of users; 33% of non-users; 17% of total). A complete list of identified themes regarding attitudes towards probiotic consumption is included in the appendix (Table A2 ).
CONCLUSION AND DISCUSSION
Here we have investigated the unmet needs of patients with ulcerative colitis (UC) from a patient perspective, by exploring the subjective impact of the disease on quality of life (QoL). The findings elucidate the omnipresent and highly integrated nature of UC's broad impact on patients' QoL, establishing effect themes throughout five interconnected core impact domains. In the Physical domain, bowel hypersensitivity to certain foods or drinks, increased stool frequency or duration, and fatigue were the most reported effects. Disease-related worries and anxieties, for instance about incontinence or developing cancer, and feelings of loss of control, for instance due to the unpredictable course and uncertain causes of UC symptoms, prevailed in the Psychological domain. Regarding Daily Activities, patients most often reported their QoL to be hampered by hospitalization, the need to quit or change jobs, and by being forced to schedule their daily life according to the disease's symptoms. A lack of understanding of UC among others, together with restricted participation in social events were the most prevalent impact themes in the context of Social Relationships, and the modification of habits (e.g. restricting consumption of certain foods or drinks) was most often reported in the Lifestyle domain. Treatment-related effects were reported throughout the five impact domains, with physical side-effects of medication being the predominant theme.
Although no conclusions on causal efficacy can be drawn due to the nature of the design, the findings favor the hypothesis of probiotic intervention representing a safe and potentially effective addition to conventional approaches for alleviating this impact and addressing the unmet patient needs: Ninety-one percent of patients reported a burden of their treatment, patients' attitudes towards applying probiotics in the management of their disease were predominantly positive, and over half of UC patients who had consumed the multispecies probiotic formulation Ecologic® 825 on a regular basis ('users') reported beneficial effects ('responders'). Probiotic effects on bowel habits were most prominent, with half of responders experiencing a decreased stool frequency as well as enhanced stool texture. Moreover, the vast majority (88%) of responders deemed the observed effects to be relevant or even highly relevant in terms of improving their QoL, whereas none of the users reported negative effects of consumption. Though it should be realized that the current study's explorative design and limited number of patients justifies only preliminary statements, these findings are promising and warrant further clinical evaluation along the chosen avenue. By clarifying effect themes throughout five interconnected core impact domains, identifying patient-relevant probiotic effects, and gaining insight into patient attitudes and consumption experiences, the current study can guide the design of such clinical follow-up research.
STUDY AND FINDINGS IN CONTEXT
It is increasingly recognized that the subjective perceptions of patients represent valuable outcomes for clinical research and practice, for patients harbor experiential knowledge that may offer unique insights into the effects of a disease and its treatment (Alrubaiy, Hutchings, & Williams, 2014; FDA, 2016; Wiklund, 2004) . Hence, revealing these insights represents an important step towards achieving optimal patient-centered health care in any area of disease (Jairath et al., 2015) . This holds particularly true however for the clinical management of UC, as our findings confirm that the burden of living with UC is comprehensive and includes intangible impact themes that may not always be apparent to the caregiver. Though there are several instruments available to these caregivers for assessing the health condition of UC patients (e.g., the Mayo Score Having qualitatively explored impact on QoL from the perspective of UC patients, and thus having established a profile of patient-relevant UC impact themes, the current study may contribute to the development of a measuring instrument that is UC-specific and appreciative of previously underexposed impact constructs.
In this respect, our UC impact profile features notable departures from the current set of PROMs for IBD. First, it adds to several existing PROMs by providing an additional level of detail. For instance, compared to the IBD Quality of Life Index-a widely applied PROM that summarizes the patient's physical, social and emotional health for the two preceding weeks-our profile includes additional patient-reports regarding UC's impact on social functioning and regarding disease-specific worries, anxieties and their underlying reasons. Compared to the IBD-Control Questionnaire-a rapid, generic PROM that focuses on disease control within four core domains, being physical, social, emotional, and treatment functioning-our overview includes a dozen bowel-related UC symptoms, rather than aggregating bowel symptoms into a single impact item. Others such as the Manitoba IBD Index and IBD Numeric Rating Scale omit symptom-level information overall.
Whereas the routine application of PROMs in day-to-day disease management is likely to benefit from simplicity and ease-of-use (Bodger et al., 2014) , a comprehensive perspective on disease impact as provided here can reveal relevant targets for treatment intervention. To illustrate, in terms of treatment decision-making one can imagine the significance of knowing whether a patient suffers from worries as a consequence of drug side-effects or from worries about having a flare. Moreover, since the fit between existing PROMs and UC patient experiences is suggested to be imperfect (Achleitner et al., 2012; Devlen et al., 2014) , establishing additional levels of detail seems a necessary step that ought to precede construct prioritization and reduction. However, although the number of interview participants was based on recommendations for qualitative data saturation, we do not claim that the provided inventory of patient-reports is exhaustive. Future research should therefore complement and validate the identified UC impact constructs.
A second noteworthy departure from existing PROMs is the integrated conceptualization of five core impact domains and a distinction between UC's direct impact and treatment-related (and as such 'indirect') impact on these domains. To our knowledge, this conceptualization represents one of the first attempts to consolidate the full burden of UC into a single framework. A holistic perspective on the burden of disease is important for not neglecting any patient-relevant constructs Supported by the patient-reports in the current study, we argue that treatment-related effects can occur in any impact domain, and that treatment should thus be visualized as an intermediary causal element between the disease and the impact domains-mediating the direct impact of the former on the latter, while also directly impacting the latter.
It has been indicated that current approaches in the clinical management of UC are limited for failing to address the full range of UC patient needs (Kemp et al., 2012) . Moreover, many treatment options are associated with negative side effects (Buchman, 2001; Warrington & Bostwick, 2006) , and indeed, 91% of patients in the current study reported a burden of treatment-related effects. Probiotics have been suggested as a promising approach to target these unmet medical needs (Celiberto et al., 2017) . Yet, the current evidence base remains insufficient to support clear efficacy verdicts due to the heterogeneous and underpowered nature of clinical studies along this line (Derikx et al., 2016 Kemp et al., 2012) . By allowing patients to freely express their experiences, the current study has induced impact constructs that appear to respond well to habitual consumption of the multispecies probiotic Ecologic® 825 and, moreover, simultaneously appear to be relevant in terms of improving QoL from the patient perspective. Positive effects were reported by 57% of users ('responders') and concerned primarily physical, bowel-related themes. A decrease in stool frequency and an enhanced stool texture were most often communicated, with 50% of responders mentioning these effects. Considering that these two effects were regarded as highly relevant in terms of improving QoL by the majority (66%) of their reporters, these represent promising end-points for subsequent clinical trials.
LIMITATIONS AND CONSIDERATIONS FOR
FUTURE RESEARCH
Based on a consideration of the design, course and outcomes of the present study, this paper concludes with suggestions to optimize follow-up research.
First of all, while the current study's inductive qualitative design fits the aim of exploring a broad range of patient perceptions, the lack of a control group may have contributed to a positive bias in reported probiotic effects. Additionally, while no effects were reported for three of the five identified impact domains, the highly integrated nature of UC's impact on patients' QoL (see 6.4.2.) does indicate the plausibility of beneficial probiotic impact in these areas. For instance, one could anticipate a decreased stool frequency (Physical domain) to have an impact on a patient's daily schedule (Daily Activities domain), when within this patient both the target symptom (i.e., increased stool frequency) and the probiotic effect (i.e., a decrease) are manifested at sufficient strength. Along the same line, while this too remains purely hypothetical, a stronger, more resilient bowel is intuitively linked to perceiving more liberty in consuming foods or drinks, plausibly alleviating the most frequently reported impact theme in the Lifestyle domain, i.e., restricted consumption of certain foods or drinks. Therefore, and needless to say, subsequent research aimed at investigating probiotic efficacy demands a robust, randomized placebo-controlled design. The finding that females significantly more often reported effects than males is noteworthy in this respect, and should be taken into account when comparing results between clinical trial arms. Furthermore, trial designs should include inclusion criteria that ensure the presence of targeted symptoms, as well as an intervention period that is adequately long for substantiating second-order effects. Moreover, it is recommended that such trials consider the stool frequency and stool texture of participants as one of their primary outcome parameters, as they were shown to be positively impacted by probiotic supplementation and may improve patient QoL in the Physical domain. In this regard, a continuous outcome superiority trial with probiotic supplementation versus placebo is arguably best suited to measure the differences between groups on these outcome parameters, contrasting our preliminary binary assessment.
Second, as with the impact of UC (6.4.2.2.)-and in agreement with the earlier identified patient expectations regarding probiotic effects (see 6.4.3.4)-several users expressed a general difficulty in confidently linking perceived effects to probiotic consumption, complicating interpretation of their reports. The use of event logs to establish a chronological chain of reports (e.g. regarding effects, diet, medication, daily activities) and to shorten recall periods could address this complication.
Third, users provided insight into factors that they perceived as potentially confounding their observation of probiotic effects. Of the eight users reporting positive effects, one mentioned increased pressure at work as a factor that might have prevented the experience of a beneficial, alleviating effect on the significant impact of fatigue on this user's QoL. Furthermore, two of these eight users reported to perceive a relatively low disease impact during the period of using the probiotic as potentially hindering the detection of more (beneficial) effects. One of these eight users reported the occasional use of a probiotic dairy drink (Yakult) as well as canabidiol oil as potentially affecting observations. Of the other users reporting no or a mere neutral effect, three users similarly mentioned to perceive a relatively low disease impact as a factor that could have prevented the detection of probiotic effects. Two expressed other possible clarifications for their lack of perceived effects, being a relatively unhealthy eating habit during the period of use and the prior use of probiotic products. A complete list of confounder-related patient-reports is included in the appendix (Table A6. 3). Taking these potentially confounding factors into account in the design of follow-up research could therefore improve the observation of patient-reported effects. Risks of confounding could for instance be reduced by qualitatively assessing the often highly patient-specific factors that are likely to influence disease symptomatology on patient intake, and subsequently minimizing the likelihood of-and monitoring for changes in their presence during the period of probiotic consumption. Suggestions for future research are summarized in Table 6 .4. Table 6 .4 Suggestions for future research based on limitations of the current study.
Features of the current study limiting the ability to identify probiotic effects:
Features of the current study limiting the ability to identify probiotic effects:
-Inductive, qualitative design aimed at exploring patient perceptions, introducing the risk of positive bias.
-Robust, randomized placebo-controlled design.
-Intervention period that is adequate for substantiating hypothesized secondorder effects. -Patient-reported difficulty in confidently linking perceived effects to specific causes, complicating reports.
-Apply event logs (e.g. daily diary apps) to establish a chronological chain of reports and shorten recall periods.
-Changes in external factors that were reported by patients to influence their UC symptoms (e.g. fatigue, stress, treatment regimen, dietary habits or supplements) during the period of probiotic consumption.
-Assess these patient-specific factors beforehand, minimize the likelihood of-and monitor for changes in their presence during intervention.
-Several users reported a relatively low impact of UC symptoms during the period of probiotic consumption, leaving little to improve.
-Select promising target endpoints (i.e. stool frequency, stool texture) and ensure the presence of their associated symptoms.
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